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Background
The clinical efficacy and safety of fludarabine combination chemotherapy was inves-
tigated for the treatment of previously untreated patients with low-grade (NHL).
Methods
Twenty-five patients who were newly diagnosed as low-grade NHL were treated with 
fludarabine combination chemotherapy. Fludarabine combination regimens consisted 
of fludarabine, mitoxantrone and dexamethasone or fludarabine, cyclophosphamide and 
mitoxantrone with or without rituximab and repeated every 4 weeks.
Results
The median age was 60 years (range, 35-77 years), with 13 of 25 patients (52%) ≥60 
years of age. Seven of 25 patients (28%) with an intermediate risk follicular lymphoma 
international prognostic index (FLIPI) and 9 of 25 patients (36%) with a high risk FLIPI 
were enrolled in this study. The delivered median number of chemotherapy was six (range, 
2-9 cycles). The overall response rate with fludarabine-based treatment was 88%, 
including 52% complete remission and 36% partial remission. During the median 
follow-up of 19 months, the estimated 2-year event-free survival was 63±10% (95% CI, 
43-83) and the 2-year overall survival was 78±9% (95% CI, 60-96). Fludarabine 
combination chemotherapy was frequently associated with grade 3 or 4 neutropenia in 
84% patients. However, neutropenic infection was observed in only one (4%) patient. Four 
patients (16%) showed grade 3 or more non-hematologic toxicities, such as acute 
coronary syndrome, intracranial hemorrhage, anaphylaxis and gastric cancer.
Conclusion
Fludarabine-combination treatment was a highly active regimen with well toleration in 
untreated low-grade NHL.
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INTRODUCTION
Low-grade non-Hodgkin’s lymphoma (NHL) is a B cell 
malignancy characterized by an indolent clinical course and 
long survival [1]. However, low-grade NHL frequently 
follows a recurrent course that can become refractory to 
conventional treatment over time, resulting in an incurable 
disease [2]. Therapeutic approaches for low-grade NHL are 
still evolving and depend on the extent of initial disease 
and treatment responses, which tend to be highly indivi-
dualized [3]. Low-grade NHL presents as a disseminated 
disease in 10-30% of cases at the time of diagnosis and relapses 
to involve distant sites after local therapy [4-6]. Therefore, 
an effective form of systemic combination therapy is im-
portant for patients with advanced stage low-grade NHL.
The response rate, progression-free survival (PFS), or 
overall survival (OS) of patients treated with anthracycline- 
containing regimens is not significantly better than those 
of patients receiving a single alkylating agent or a cyclo-
phosphamide, vincristine, and prednisone (CVP) regimen 
for treating low-grade NHL [7-9]. Fludarabine is a purine 
analogue and is one of the most effective drugs for treating 
low-grade NHL; fludarabine-treated patients exhibit better Korean J Hematol 2011;46:180-5.
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PFS than CVP-treated patients [10]. Fludarabine combined 
with mitoxantrone, cyclophosphamide, and rituximab have 
synergistic effects in sensitizing drug-resistant lymphoma 
cell lines to cytotoxic chemotherapy in vitro [11, 12]. To 
improve the efficacy of fludarabine as a single agent, various 
combination therapies have been reported to achieve ex-
cellent anti-tumor effects and are comparable or superior 
to fludarabine alone [13]. Fludarabine combination chemo-
therapy improves clinical response to 70-90% and prolongs 
PFS in patients with newly diagnosed, relapsed, or refractory 
low-grade NHL [14-16]. However, there are some limitations 
to apply fludarabine combination chemotherapy for treating 
indolent lymphoid malignancies; in particular, this regimen 
has no survival benefit, causes long-lasting myelosuppression, 
and increases the risk of opportunistic infections [17, 18]. 
Brown et al. assessed cases of advanced marginal zone B 
cell lymphoma and concluded that fludarabine combination 
chemotherapy is unsuitable due to significant hematologic 
toxicity and increased risk of infections, both during and 
after therapy [17]. In contrast, others have advocated the 
superior efficacy of fludarabine combination chemotherapy 
with mild toxicities [19, 20].
Therefore, we assessed the clinical efficacy and toxicity 
of fludarabine combination chemotherapy for treatment of 
patients with low-grade NHL.
MATERIALS AND METHODS
1. Patients
Between January 2004 and May 2010, 25 previously un-
treated patients with low-grade NHL were enrolled in the 
study. Patients who met the following criteria were con-
sidered eligible for inclusion in the study: ≥18 years of 
age; Eastern Cooperative Oncology Group (ECOG) perfor-
mance status ＜3; pathologically confirmed follicular lymp-
homa, small lymphocytic lymphoma, or marginal zone B 
cell lymphoma; Ann Arbor stage of non-continuous II or 
III-IV disease potentially incurable by local radiation the-
rapy; and at least 1 measurable tumor mass on a conventional 
computed tomography (CT) scan. Exclusion criteria were 
as follows: previous exposure to a purine analogue; typical 
chronic lymphocytic leukemia; HIV-positive status; history 
of malignant diseases; ECOG ≥3; renal and/or hepatic 
function ＞2× the upper normal limit; or stage I or II NHL 
with asymptomatic disease.
2. Treatment
Twenty-two patients were treated using FND chemothe-
rapy (fludarabine, 25 mg/m
2 daily for 3 days; mitoxantrone, 
10 mg/m
2 on day 1; and dexamethasone, 20 mg/m
2 daily 
for 5 days, every 4 weeks); 2 patients were treated using 
FCM chemotherapy (fludarabine, 25 mg/m
2 daily for 3 days; 
cyclophosphamide, 200 mg/m
2 daily for 3 days; and mito-
xantrone, 8 mg/m
2 on day 1, every 4 weeks); and 1 patient 
received FCM with rituximab (375 mg/m
2 on day 1). Subse-
quent cycles of chemotherapy were administered, if patients 
fulfilled the following criteria: neutrophil count ＞1.0×10
9/L; 
platelet count ＞75×10
9/L. In patients not achieving these 
criteria at 4 weeks, treatment was delayed for up to 2 weeks 
and restarted at the initial dose. If the neutrophil count 2 
weeks later was ＜1×10
9/L or the platelet count was ＜75×10
9/L, 
the following cycle was administered at 75% of the initial 
dose after the neutrophil and platelet counts recovered. 
Granulocyte-colony stimulating factor (G-CSF) was admini-
stered in patients with neutropenia grade 3 or higher. 
Toxicity was evaluated according to the Common Termino-
logy Criteria for Adverse Events (CTCAE; version 3.0).
3. Assessment
Tumor assessments were based on a CT scan of the neck, 
thorax, abdomen, and pelvis. Treatment response was asse-
ssed at 4 weeks after 3 or 4 cycles of primary chemotherapy, 
if there was no evidence of disease progression. Patients 
who achieved partial (PR) or complete remission (CR) re-
ceived additional cycles of chemotherapy (the same regi-
men). If patients with stage II NHL improved, the primary 
lesion within the radiation field was treated by involved 
field radiation therapy (IFRT). A follow-up CT scan, blood 
count, and chemistry profiling for tumor response after 
treatment was performed 4 weeks after the last treatment, 
every 3 months for the first year, every 6 months for the 
next 2 years, and yearly thereafter until relapse. Response 
was assessed using the revised response criteria for malignant 
lymphoma as described by Cheson et al. [21]. CR was defined 
as the disappearance of all evidence of disease and PR was 
defined as a ≥50% decrease in the sum of the product 
of the diameters of up to 6 dominant masses with no increase 
in the size of other nodes. Progressive disease (PD) was 
defined as any new lesion o r  a n  i n c r e a s e  o f  ≥50% of 
previously involved sites from the nadir, and patients not 
included in any of these categories were considered to have 
stable disease (SD).
4. Statistical analysis
The primary end-points of the study were the overall 
response rate (ORR; CR＋PR) and toxicities. Secondary end- 
points included event-free survival (EFS) and OS. EFS was 
measured from date of study entry to the date of disease 
progression, recurrence, or death from any cause, and OS 
was measured from the date of study entry to death from 
any cause. Survival analysis was performed according to the 
Kaplan-Meier method using SPSS 17.0 (SPSS, Inc., Chicago, 
IL, USA).
RESULTS
1. Patient characteristics and treatment outcome
Twenty-five patients (9 patients with small lymphocytic 
lymphoma, 4 patients with follicular lymphoma, and 12 
patients with marginal zone B cell lymphoma) were enrolled 
in this study. The tumors in 12 patients with marginal zone 
B cell lymphoma were sub-classified as extranodal marginal Korean J Hematol 2011;46:180-5.
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Table 1. Characteristics of 25 patients with low-grade non- 
Hodgkin’s lymphoma.
N (%)
Age, median (range) year 60 (35-77)
Male/Female 15/10
Disease
  SLL   9 (36)
  FL   4 (16)
  MZBCL 12 (48)
Ann Arbor stage 
  II   7 (28)
  III   5 (20)
  IV 13 (42)
IPI
  Low   9 (36)
  Low-intermediate 10 (40)
  High-intermediate   5 (20)
  High   1 (4)
FLIPI
  Low   9 (36)
  Intermediate   7 (28)
  High   9 (36)
ECOG PS
  0 10 (40)
  1 12 (48)
  2   3 (12)
Treatment type
  FND 22 (88)
  FCM±R   3 (12)
Abbreviations: SLL, small lymphocytic lymphoma; FL, follicular 
lymphoma; MZBCL, marginal zone B cell lymphoma; IPI, inter-
national prognostic index; FLIPI, follicular lymphoma international 
prognostic index; PS, performance scale; FND, fludarabine, mito-
xantrone, and dexamethasone; FCM±R, fludarabine, cyclopho-
sphamide, and mitoxantrone±rituximab.
Table 2. Treatment result of fludarabine-combination chemothe-
rapy according to tumor subtype.
CR PR SD＋PD OR (%)
Small lymphocytic lymphoma   4 3 2     7/9 (78)
Follicular lymphoma   3 1 0     4/4 (100)
Marginal zone B cell lymphoma   6 5 1 11/12 (92)
Total 13 9 3 22/25 (88)
Abbreviations: CR, complete response; PR, partial response; SD, 
stable disease; PD, progressive disease; OR, overall response.
Fig. 1. Event-free survival and overall survival following fludarabine 
combination chemotherapy in untreated indolent non-Hodgkin’s
lymphoma.
zone B cell lymphoma (11 patients) including tumors in 
6 patients with gastric involvement, or nodal marginal zone 
B cell lymphoma. The median age was 60 years (range, 35-77 
years), with 13 of 25 patients (52%) ≥60 years of age. Seven 
of 25 patients (28%) with an intermediate-risk follicular 
lymphoma international prognostic index (FLIPI) and 9 of 
25 patients (36%) with a high-risk FLIPI were enrolled in 
this study. Pre-treatment patient characteristics are 
summarized in Table 1.
Three patients (12%) had PD after the 2
nd cycle of FND 
chemotherapy; 2 SLL patients exhibited an incremental 
increase in palpable lymph nodes, and 1 patient with gastric 
extranodal marginal zone B cell lymphoma developed 
obstructive symptoms after 2 cycles of chemotherapy; thus, 
using early CT scans, we confirmed that these symptomatic 
patients had PD. After 3 or 4 cycles of fludarabine com-
bination chemotherapy, interim ORR was achieved in 22 
patients (88% [CR, 36% and PR, 52%, respectively]). At 
the end of planned chemotherapy, 22 of 25 patients (88%) 
showed an ORR of 52% (13/25 [CR]) and 36% (9/25 [PR]; 
Table 2). After a median follow-up of 19 months, 9 patients 
experienced disease progression, refractory disease, or death; 
3 patients had refractory disease during treatment; 5 patients 
showed disease progression after achieving PR (2 patients) 
or CR (3 patients); and 1 patient developed a life-threatening 
intracranial hemorrhage during chemotherapy. Five patients 
with disease progression and 1 patient with refractory disease 
received salvage chemotherapy and 2 other patients did not 
receive additional chemotherapy due to poor general health. 
One patient showed PR after salvage chemotherapy and 
was treated using 
90Y-Ibritumomab tiuxetan; the other 
patient achieved CR after salvage chemotherapy. Both 
patients maintained CR until the final follow-up. During 
a median follow-up of 19 months, the estimated 2-year EFS 
was 63±10% (95% CI, 43-83) and the 2-year OS was 78±9% 
(95% CI, 60-96; Fig. 1).
2. Toxicity
The median number of chemotherapy cycles was 6 (range, 
2 - 9 ) .  F o u r  p a t i e n t s  r e c e i v e d  o n l y  2  c y c l e s  o f  f l u d a r a b i n e  
combination chemotherapy; 3 of the 4 patients could not 
continue the scheduled chemotherapy due to disease pro-
gression. One patient developed unstable angina irrelevant 
to the infusion reaction after the 2
nd cycle of chemotherapy; 
this patient achieved PR after 2 cycles of chemotherapy 
and additional chemotherapy was substituted by IFRT.
The major toxicities of fludarabine combination chemo-
therapy were hematologic. A total of 133 cycles of che-Korean J Hematol 2011;46:180-5.
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Table 3. Adverse events during fludarabine-combination chemo-
therapy according to cycles and patients.
Toxicity
Cycles (%), N=133
Grade 1 Grade 2 Grade 3 Grade 4
Leukopenia   6 (4.5) 29 (21.8) 53 (43.6) 28 (21.1)
Neutropenia  14 (10.5) 28 (21.1) 40 (30.1) 37 (27.8)
Anemia 53 (39.8)   8 (6.0)   3 (2.3)    −
Thrombocytopenia 47 (35.3)   8 (6.0)    −   1 (0.8)
Dyspnea   1 (0.8)   2 (1.5)    −    −
Anorexia   3 (2.3)   1 (0.8)    −    −
Nausea   2 (1.5)   1 (0.8)    −    −
Vomiting     −   1 (0.8)    −    −
Elevated AST/ALT     −   2 (1.5)    −    −
Sensory neuropathy   1 (0.8)   1 (0.8)    −    −
Motor neuropathy   4 (3.0)   2 (1.5)    −    −
Fatigue     −   1 (0.8)    −    −
Insomnia   2 (1.5)   1 (0.8)    −    −
Dizziness   4 (3.0)     −    −    −
Constipation   1 (0.8)   1 (0.8)    −    −
Diarrhea     −   1 (0.8)    −    −
Mucositis   2 (1.5)     −    −    −
Neutropenic fever     −     − 1 (0.8)    −
Pruritus   4 (3.0)     −    −    −
Patients (%), N=25
Grade 1 Grade 2 Grade 3 Grade 4
Leukopenia     −     − 11 (44) 12 (48)
Neutropenia      − 2 (8)   8 (32) 13 (52)
Anemia 12 (48) 6 (24)   1 (4)     −
Thrombocytopenia 11 (44) 3 (12)     −   1 (4)
Infection     −     −   1 (4)     −
Acute coronary      −     −   1 (4)     −
  syndrome
Intracranial      −     −     −   1 (4)
  hemorrhage
Anaphylaxis     −     −   1 (4)     −
Gastric cancer during     −     −   1 (4)     −
  Follow-up
Abbreviations: AST, aspartate aminotransferase; ALT, alanine 
transaminase.
motherapy were administered. Grades 3 and 4 leukopenia 
were observed in 43.6% and 21.1% of the patients, 
respectively, and grades 3 and 4 neutropenia occurred in 
30.1% and 27.8% of the patients, respectively (Table 3). 
On per patient-treated basis, 52% of the patients experienced 
grade 4 neutropenia during chemotherapy. Grade 3 or more 
anemia and thrombocytopenia were rarely observed. Only 
one (4%) patient developed neutropenic fever during chemo-
therapy, which improved after subsequent neutrophil 
recovery. There were no life-threatening infections during 
fludarabine-containing chemotherapy. In 2 patients (8%), 
the next scheduled chemotherapy was delayed for 2 weeks 
due to neutropenia; however, discontinuation of fludarabine- 
containing chemotherapy due to hematologic toxicities did 
not occur. Non-hematologic toxicities were generally mild 
and manageable (Table 3). Grade 3 or higher non-hemato-
logic adverse events developed in 4 patients (16%). One 
patient developed unstable angina as mentioned, and 1 
patient experienced intracranial hemorrhage on day 9 of 
the 5
th cycle; at that time, the patient had a normal platelet 
count and a normal coagulation profile. During the second 
cycle of fludarabine infusion, one patient developed grade 
3 anaphylaxis with hypotension, skin rash, and fever. This 
patient was treated using hydrocortisone and anti-histamine, 
resulting in immediate improvement; thus, the planned 
chemotherapy was completed without dose reduction. One 
patient underwent surgical resection due to early gastric 
adenocarcinoma 36 months after completing fludarabine- 
combination chemotherapy.
DISCUSSION
Conventional therapy for low-grade NHL is based on the 
use of alkylating agents or combination therapy with or 
without anthracyclines. Recently, fludarabine, a purine ana-
logue, was actively studied in patients with indolent lymp-
homa. Over the past 10 years, fludarabine has improved 
the clinical response and PFS in patients with indolent 
lymphomas.
We analyzed the safety and clinical efficacy of fludarabine 
combination chemotherapy for patients with previously 
untreated stage II-IV low-grade NHL. We showed that ORR 
was 88% (CR, 52% and PR, 36%) and 2-year EFS was 78%. 
Thus, the response rate was reasonable in comparison with 
that obtained using other agents as a first-line treatment 
for patients with low-grade NHL. CVP and fludarabine 
monotherapy yielded ORRs of 52-70% and CR rates of 
15-39%, respectively, and a median 2-year time to progres-
sion rate of approximately 40% [22]. In other studies, the 
ORRs obtained using fludarabine combination chemothe-
rapy as first-line treatment were 72-94% [23-26]. The high 
efficacy and long duration of PFS in our study suggest that 
fludarabine combination chemotherapy is a reasonable op-
tion in patients with untreated low-grade NHL.
Hematologic toxicity is a major common complication 
resulting from using fludarabine as a chemotherapeutic agent. 
Fludarabine monotherapy has a reported grade 3 or greater 
neutropenia rate of 23-27% [22, 27]. Combination fluda-
rabine monotherapy with other drugs increased the severity 
of the neutropenia, particularly when fludarabine was 
administered in combination with rituximab. Fludarabine 
combination with rituximab in indolent lymphoma results 
in grade 4 neutropenia in 36-66% of patients [16, 17, 28], 
and 27% of patients experienced at least 1 episode of grade 
≥3 infection during chemotherapy [16]. We observed that 
neutropenia is a major problem during chemotherapy. Grades 
3 and 4 neutropenia were observed during 30% and 28% 
of treatment cycles and 52% of patients experienced grade 
4 neutropenia during chemotherapy. The association with 
serious infection during fludarabine combination chemo-
therapy has been reported with varying incidences. Tam 
et al. [16] reported that 27% of patients had grade ≥3 
infection when treated with fludarabine, cyclophosphamide, 
and rituximab (FC-R) combination therapy. Ferrario et al. 
[15] reported 6.3% of patients (4/63) experienced early death Korean J Hematol 2011;46:180-5.
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during the prolonged post-chemotherapy aplasic phase when 
treated with fludarabine and cyclophosphamide combination 
therapy [15]. However, Tobinai et al. [28] showed that only 
7% (3/41) of patients developed grade 3 infection with no 
grade 4 infection with oral fludarabine in combination with 
rituximab, despite severe neutropenia. In our study, only 
1 patient (4%) experienced neutropenic fever without grade 
4 infection and no patients required dose modification of 
chemotherapy or a delay in treatment for greater than 2 
weeks. Proper use of G-CSF and selection of patients from 
a previously untreated group may reduce infectious episodes 
despite resulting in severe neutropenia. In this study, 2 
patients (8%) experienced a delay in the next scheduled 
chemotherapy for 2 weeks due to neutropenia without dose 
reduction. The short duration of neutropenia likely infl-
uenced the rare occurrence of serious infections. The other 
most important complication after fludarabine-based chemo-
therapy is secondary malignancy. One patient developed 
solid cancer after completing fludarabine combination treat-
ment, but hematopoietic malignancies, such as myelody-
splasia or acute myeloid leukemia, were not observed.
In conclusion, fludarabine combination chemotherapy is 
a highly effective regimen with a high response rate, tolerable 
toxicities, and long survival in patients with untreated 
low-grade NHL. 
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